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ABSTRACT
Objective: To report safety and efficacy outcomes from up to 9 years of treatment with terifluno-
mide in an extension (NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis
Oral (TEMSO) trial (NCT00134563).
Methods: A total of 742 patients entered the extension. Teriflunomide-treated patients continued
the original dose; those previously receiving placebo were randomized 1:1 to teriflunomide 14mg
or 7 mg.
Results: By June 2013, median (maximum) teriflunomide exposure exceeded 190 (325) weeks per
patient; 468 patients (63%) remained on treatment. Teriflunomide was well-tolerated with contin-
ued exposure. Themost common adverse events (AEs) matched those in the core study. In extension
year 1, first AEs of transient liver enzyme increases or reversible hair thinning were generally attrib-
utable to patients switching from placebo to teriflunomide. Approximately 11% of patients discon-
tinued treatment owing to AEs. Twenty percent of patients experienced serious AEs. There were 3
deaths unrelated to teriflunomide. Soon after the extension started, annualized relapse rates and
gadolinium-enhancing T1 lesion counts fell in patients switching from placebo to teriflunomide, re-
maining low thereafter. Disability remained stable in all treatment groups (median Expanded Disabil-
ity Status Scale score #2.5; probability of 12-week disability progression #0.48).
Conclusions: In the TEMSO extension, safety observations were consistent with the core trial,
with no new or unexpected AEs in patients receiving teriflunomide for up to 9 years. Disease
activity decreased in patients switching from placebo and remained low in patients continuing
on teriflunomide.
Classification of evidence: This study provides Class III evidence that long-term treatment with ter-
iflunomide is well-tolerated and efficacy of teriflunomide is maintained long-term. Neurology®
2016;86:920–930
GLOSSARY
AE 5 adverse event; ALT 5 alanine aminotransferase; ARR 5 annualized relapse rate; EDSS 5 Expanded Disability Status
Scale; Gd 5 gadolinium; IFN 5 interferon; MS 5 multiple sclerosis; OI 5 opportunistic infection; RMS 5 relapsing multiple
sclerosis; RRMS5 relapsing-remitting multiple sclerosis; TEMSO5 Teriflunomide Multiple Sclerosis Oral; ULN5 upper limit
of normal.
Teriflunomide (Aubagio; Genzyme, Cambridge, MA) is a once-daily oral immunomodulator
approved for relapsing-remitting multiple sclerosis (RRMS). Teriflunomide selectively and
reversibly inhibits dihydro-orotate dehydrogenase, a key mitochondrial enzyme in de novo
pyrimidine synthesis. This exerts a cytostatic effect on proliferation of activated T and B lym-
phocytes, potentially limiting their contribution to multiple sclerosis (MS) pathogenesis.1
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Three randomized placebo-controlled trials
in relapsing MS supported the registration and
approval of teriflunomide for RRMS treatment.
Collectively, these studies demonstrated efficacy
of teriflunomide on disability, annualized relapse
rate (ARR), and MRI markers of disease.2–4 The
trials demonstrated a consistent safety and toler-
ability profile for teriflunomide used for 2
years.2–4 A randomized trial comparing subcuta-
neous interferon (IFN)–b-1a with terifluno-
mide in relapsing MS demonstrated that
efficacies of teriflunomide 14 mg and IFN-b-
1a were in the same range, and treatment satis-
faction was greater with teriflunomide.5
To collect long-term safety data and
monitor disease activity with continued teri-
flunomide treatment, extension studies were
established. An extension of the phase 2 study
(NCT00228163, initially including 147 pa-
tients)6 has followed patients for up to 12
years,7,8 the longest clinical trial of any oral
disease-modifying therapy for MS. Analyses
at 8.5 years showed that teriflunomide main-
tained its established safety and tolerability
profile, with disease activity remaining low6;
disease activity remained low with longer
follow-up.7,8 Teriflunomide Multiple Sclerosis
Oral (TEMSO), the first pivotal, phase 3, ran-
domized controlled trial of teriflunomide,
lasted 2 years.3 We present safety and efficacy
outcomes from up to 7 years of follow-up in
an extension of the TEMSO trial (9 years of
follow-up since randomization).
Clinical trials (clinicaltrials.gov) identifiers
are as follows: TEMSO: NCT00134563;
TEMSO extension: NCT00803049.
METHODS Study population. Inclusion and exclusion cri-
teria for the core TEMSO study have been reported elsewhere3
and are summarized in appendix e-1 on the Neurology® Web site
at Neurology.org.
Study design. TEMSO was a multinational, multicenter, ran-
domized, placebo-controlled, double-blind, parallel-group study
in patients with relapsing MS (RMS).3 Patients were initially
randomized 1:1:1 to receive once-daily oral teriflunomide 14 mg
or 7 mg, or placebo, for 108 weeks. Upon completion of the study,
patients were eligible to enter the long-term extension; those already
receiving teriflunomide remained on their original dose (in a
blinded fashion), while those previously receiving placebo were
randomized 1:1 to teriflunomide 14 mg or 7 mg.
Study objectives. The primary objective of the TEMSO exten-
sion was to assess long-term safety of teriflunomide in patients with
RMS. Secondary objectives included assessment of long-term
efficacy of teriflunomide on disability progression (primary
efficacy endpoint) and on ARR and MRI variables.
Standard protocol approvals, registrations, and patient
consents. The study was conducted in accordance with the
International Conference on Harmonisation Guidelines for Good
Clinical Practice and the Declaration of Helsinki. The protocol
was approved by central and local ethics committees. Patients
provided written informed consent before commencement of
TEMSO and again before entry into the extension.
Study procedures. Safety was assessed by monitoring adverse
events (AEs), vital signs, and laboratory parameters throughout
the core study and extension. Laboratory tests were conducted
every 2 weeks for the first 24 weeks of the extension and every
6 weeks thereafter. Safety analyses are based on AEs reported
by the patient or noted by the investigator. AEs included any
event that developed/worsened after first dose of study drug.
An event was classed as serious if it resulted in death, was life-
threatening, required inpatient hospitalization/prolongation of
existing hospitalization, resulted in persistent or significant
incapacity, was a birth defect, or was medically important.
Events of special interest were based on currently available
preclinical and clinical data, recognized class effects, and the
potential mechanism of action of teriflunomide.
Relapses were recorded throughout the study and extension.
Definitions of relapse and confirmed relapse have been pub-
lished.3 Assessments of disability (Expanded Disability Status
Scale [EDSS] scores) and MRI measures of disease are described
in appendix e-1.
Statistical analysis. Results are from an interim analysis with a
cutoff date of June 28, 2013, conducted for regulatory purposes.
Analyses were reported under 4 treatment groups by core study
and extension treatment group (i.e., teriflunomide 14 mg/
14 mg; placebo/14 mg; teriflunomide 7 mg/7 mg; placebo/7 mg).
Safety evaluations were conducted in the safety population ac-
cording to treatment received. Here, we present safety data for the
extension study only.
Efficacy data presented here include data from the core study
(for patients who entered the extension) as a reference. Efficacy
analyses, performed on the modified intent-to-treat population
(defined as all patients who received $1 dose of study treatment
in the extension), are described in appendix e-1.
Classification of evidence. This study provides Class III evi-
dence: it was a randomized, dose-blind, controlled clinical trial of
teriflunomide with objective outcome assessment of safety and
efficacy in a representative population. Baseline characteristics
were substantially equivalent among treatment groups. Treatment
allocation was concealed, and the primary outcome (tolerability)
and exclusion/inclusion criteria were defined.
RESULTS Study disposition.Of the 796 patients who
completed the 108-week TEMSO core study, 742
(93%) entered the extension, representing 68% of
the 1,088 patients randomized in the core study
(figure 1). Two patients were randomized to the
teriflunomide 14-mg/14-mg group but not treated
in the extension. Therefore, the safety population
comprised 740 patients. At the cutoff date, 468
patients (63%) remained in the extension.
Cumulative teriflunomide exposure (from start of
core study to interim analysis cutoff) was 1,479, 348,
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1,452, and 453 patient-years for the 14-mg/14-mg,
placebo/14-mg, 7-mg/7-mg, and placebo/7-mg
groups, respectively. Corresponding median (maxi-
mum) duration of exposure per patient was 324
(448), 200 (325), 299 (457), and 192 (340) weeks,
respectively.
The percentage of patients discontinuing treat-
ment, and reasons for discontinuation, were similar
overall among the 4 treatment groups. The most fre-
quent reasons for discontinuation were withdrawal of
consent and AEs (figure 1). In extension year 1, more
patients switching from placebo to teriflunomide dis-
continued treatment overall compared with patients
continuing on teriflunomide (figure e-1). The pro-
portion of patients discontinuing treatment then
declined over the course of the extension.
Baseline characteristics (at core study entry). Baseline
demographics and disease characteristics of patients
who entered the extension were well-balanced across
treatment groups (table 1).
Patients who did not enter the extension. Baseline data
for those patients who did not enter the extension
are shown in table e-1. This group had a higher mean
EDSS score and more gadolinium (Gd)–enhancing
T1 lesions at core study baseline and a greater pro-
portion of patients with progressive disease compared
with patients who entered the extension. These pa-
tients also had higher ARR and increased risk of dis-
ability progression at the end of the core study
(table e-2).
Safety and tolerability. Overview. Over the extension,
approximately 90% of patients reported at least
1 AE (table 2). The majority (;80%) of patients
who entered the extension experienced an AE in
extension year 1. Consistent with findings in the core
study, the most commonly reported AEs in the exten-
sion were nasopharyngitis, headache, and alanine
aminotransferase (ALT) increase. Serious AEs were
evenly distributed across groups, with no evidence
of a dose effect (tables 2 and e-3A). AEs leading to
Figure 1 Patient disposition in Teriflunomide Multiple Sclerosis Oral (TEMSO) and the TEMSO extension study
a The major reason for screening failure was failure to meet inclusion criteria (n 5 155 [62.0%]); b 2 patients (1 each in the 14-mg and 7-mg teriflunomide
groups) were not exposed to study medication because of protocol violation; c did not give consent to continue in extension study; d 2 patients in the 14-mg/
14-mg group were randomized but not treated: 1 did not wish to continue and the other 1 prematurely discontinued study treatment and did not take any
double-blind medication in the extension.
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discontinuation were reported in 82 patients (11% of
the study population) without a dose effect (tables 2
and e-3B). The most common reason for discontin-
uation was confirmed ALT increase, which was
required by protocol for ALT elevations .33 upper
limit of normal (ULN) confirmed by a repeated mea-
surement. Other AEs leading to discontinuation were
relatively infrequent. Generally, for each individual
AE, the number of episodes per patient was low
(#2.0) and similar across teriflunomide groups
(table e-3C).
Hepatic disorders. The most commonly reported
hepatic disorder–related AEs were transient ALT
elevations, reported as an AE as required by protocol.
These occurred at a broadly similar incidence in the 4
treatment groups, and, as noted above, some cases led
to treatment discontinuation (table 2). In extension
year 1, first ALT elevations were more common in
patients switching from placebo to teriflunomide
than in patients continuing on teriflunomide; how-
ever, in subsequent years, first ALT elevations were
low in all treatment groups. Patients with confirmed
ALT elevations .33 ULN were monitored until
their ALT levels normalized, and patients with ALT
elevations of 2–33 ULN were monitored weekly
until ALT was ,1.53 ULN. ALT elevations were
Table 1 Patient demographics and clinical and MRI characteristics at start of core Teriflunomide Multiple
Sclerosis Oral (TEMSO) study for patients entering extension (randomized population)
Teriflunomide
14 mg/14 mg
(n 5 253)
Placebo/
teriflunomide
14 mg (n 5 108)
Teriflunomide
7 mg/7 mg
(n 5 252)
Placebo/
teriflunomide
7 mg (n 5 129)
Demographics
Age, y, mean (SD) 38.6 (8.4) 37.6 (8.5) 38.0 (8.8) 39.6 (8.5)
Female, n (%) 182 (71.9) 85 (78.7) 175 (69.4) 94 (72.9)
Caucasian/white, n (%) 248 (98.4) 105 (98.1) 245 (97.6) 128 (99.2)
Region, n (%)
Americas 58 (22.9) 25 (23.1) 62 (24.6) 34 (26.4)
Eastern Europe 74 (29.2) 36 (33.3) 75 (29.8) 44 (34.1)
Western Europe 121 (47.8) 47 (43.5) 115 (45.6) 51 (39.5)
Clinical disease characteristics
Mean (SD) time from first
symptoms of MS, y
9.14 (6.98) 7.78 (6.39) 8.64 (7.05) 8.24 (6.51)
No. relapses within past 12
months
Mean (SD) 1.3 (0.7) 1.4 (0.7) 1.4 (0.7) 1.3 (0.6)
Median (range) 1.0 (0.0–4.0) 1.0 (0.0–4.0) 1.0 (0.0–4.0) 1.0 (0.0–3.0)
MS subtype, n (%)
Relapsing-remitting 241 (95.3) 101 (93.5) 232 (92.1) 117 (90.7)
Secondary progressive 6 (2.4) 3 (2.8) 9 (3.6) 6 (4.7)
Progressive relapsing 6 (2.4) 4 (3.7) 11 (4.4) 6 (4.7)
EDSS score
Mean (SD) 2.60 (1.17) 2.37 (1.24) 2.59 (1.28) 2.76 (1.33)
Median (range) 2.5 (0.0–5.5) 2.0 (0.0–5.5) 2.5 (0.0–5.5) 2.5 (0.0–6.0)
MRI characteristics
Total lesion volume, mL
Mean (SD) 17.28 (16.47) 20.13 (20.09) 20.64 (20.35) 17.36 (16.98)
Median (range) 11.41 (0.4–82.7) 12.38 (0.4–83.7) 14.04 (0.2–146.3) 11.18 (0.1–77.0)
Gd-enhancing T1 lesions, n
Mean (SD) 1.64 (5.26) 1.27 (2.43) 1.54 (3.81) 1.38 (3.44)
Median (range) 0.00 (0.0–50.0) 0.00 (0.0–12.0) 0.00 (0.0–38.0) 0.00 (0.0–26.0)
Abbreviations: EDSS 5 Expanded Disability Status Scale; Gd 5 gadolinium; MS 5 multiple sclerosis.
There were no significant differences between groups in demographics or disease characteristics (all p . 0.05) as tested
by analysis of variance (age, time since first symptoms of MS, EDSS score, total lesion volume) or x2 test (all other items).
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reversible in the majority of patients; for patients with
ALT.33ULN, median time to ALT normalization
(to baseline or # ULN) was 40 days, and 9 patients
(11.4%) had values that did not return to normal.
Two patients had ALT levels $33 ULN and total
bilirubin $23 ULN, but these were explained by
hepatitis A infection (patient discontinued owing to
the hepatic enzyme elevation) and gallbladder disease
(patient subsequently discontinued owing to gallblad-
der disease), respectively, and therefore did not meet
the criteria for Hy law.
Malignancies. There was no specific pattern of
occurrence with respect to the cases of malignancies
reported in the extension (table 2). No hematologic
cancers (i.e., leukemia or lymphoproliferative tumors)
were reported. The overall incidence of malignancies
Table 2 Adverse events (AEs) occurring in the extension (safety population)
Incidence
Teriflunomide
14 mg/14 mg
(n 5 250)
Placebo/
teriflunomide
14 mg (n 5 106)
Teriflunomide
7 mg/7 mg
(n 5 254)
Placebo/
teriflunomide
7 mg (n 5 130)
Overview, n (%)a
Any AE 224 (89.6) 97 (91.5) 230 (90.6) 122 (93.8)
Serious AE 55 (22.0) 19 (17.9) 62 (24.4) 30 (23.1)
AE leading to death 1 (0.4) 0 1 (0.4) 1 (0.8)
AE leading to permanent treatment
discontinuation
24 (9.6) 11 (10.4) 29 (11.4) 18 (13.8)
First AE occurrence
Year 1 of extension study 193 (77.2) 90 (84.9) 199 (78.3) 102 (78.5)
Year 2 of extension studyb 14 (28.0) 4 (25.0) 14 (29.2) 9 (34.6)
Years 3–7 of extension studyb 16 (50.0) 3 (27.3) 14 (46.7) 10 (58.8)
Key AEs of interest, alanine aminotransferase
increases, n (%)a
Any AE 36 (14.4) 19 (17.9) 39 (15.4) 20 (15.4)
Serious AE 7 (2.8) 3 (2.8) 3 (1.2) 4 (3.1)
AE leading to permanent treatment
discontinuation
9 (3.6) 4 (3.8) 7 (2.8) 5 (3.8)
First AE occurrence
Year 1 of extension study 17 (6.8) 15 (14.2) 21 (8.3) 15 (11.5)
Year 2 of extension studyc 6 (2.8) 1 (1.3) 7 (3.4) 2 (2.1)
Years 3–7 of extension studyc 13 (6.8) 3 (4.2) 11 (6.3) 2 (2.3)
Key AEs of interest, malignanciesd
Thyroid neoplasm 2 (1,786, 1,096) — — —
Lip neoplasm 1 (1,076)
Adrenal and breast neoplasme 1 (adrenal, 1,094;
breast, 1,210)
— — —
Glioma — 1 (608) — —
Cervical carcinoma — — 1 (2,280) —
Breast cancer — — 1 (2,668) —
Hepatic cancer — — 1 (2,630) —
Basal cell carcinoma — — — 1 (140)
Metastatic colon cancer — — — 1 (756)
aNumbers are for patients reporting an AE.
bPatients with a first event were censored, numbers at risk in year 2 were as follows: 14 mg/14 mg, 50; placebo/14 mg,
16; 7 mg/7 mg, 48; placebo/7 mg, 26; numbers at risk in year 3 were as follows: 14 mg/14 mg, 32; placebo/14 mg, 11;
7 mg/7 mg, 30; placebo/7 mg, 17.
c Patients with a first event were censored, numbers at risk in year 2 were as follows: 14 mg/14 mg, 217; placebo/14 mg,
79; 7 mg/7 mg, 204; placebo/7 mg, 97; numbers at risk in year 3 were as follows: 14 mg/14 mg, 190; placebo/14 mg, 72;
7 mg/7 mg, 176; placebo/7 mg, 87.
dData reported as n (time from first dose to onset, days).9
eOccurring in the same patient.
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was 0.01 (mean follow-up 5.2 years), comparable to
the general MS population in Sweden (0.11, mean
follow-up 35.1 years).9
Peripheral neuropathy. Peripheral neuropathy con-
firmed via electrophysical nerve conduction tests
was reported for 9 patients receiving teriflunomide
14 mg (1 of whom had 2 events) and 5 patients
receiving 7 mg. At the data cut, 8 events were ongo-
ing, 3 were resolved with sequelae (mean duration
267 days), and 4 were resolved without sequelae
(mean duration 429 days). Three patients discontin-
ued owing to peripheral neuropathy (of these, 2 were
classed as polyneuropathy); all 3 cases were consid-
ered potentially related to treatment.
Infections. Infections were mainly mild in severity
and of upper respiratory tract origin, including naso-
pharyngitis, influenza, sinusitis, and upper respiratory
tract infections; there were few serious infections.
Opportunistic infections (OIs)10 were uncommon.
The most frequent OI was oral herpes, which
occurred in 2.0%, 4.7%, 7.1%, and 2.3% of patients
in the 14-mg/14-mg, placebo/14-mg, 7-mg/7-mg,
and placebo/7-mg groups, respectively. There was a
single OI event classified as serious in a patient in the
7-mg/7-mg group with oral herpes on day 1,011; the
patient recovered in 9 days and did not discontinue
treatment. There were no cases of tuberculosis and no
discontinuations owing to OIs.
Hematologic disorders. Neutropenia was reported in
2.8%, 5.7%, 2.4%, and 1.5% of patients in the 14-
mg/14-mg, placebo/14-mg, 7-mg/7-mg, and pla-
cebo/7-mg groups, respectively. Leukopenia was
reported in 2.0%, 3.8%, 3.5%, and 1.5% of patients,
respectively. Six patients discontinued teriflunomide
following hematologic disorders (appendix e-1),
including patients with neutrophil counts ,109/L,
who were required to discontinue study treatment
by protocol. Leukocyte and neutrophil counts over
time in the whole study population, and neutrophil
counts in patients who discontinued, are shown in
figures e-2A and e-2B, respectively.
Hair thinning. Hair thinning (coded as alopecia)
was reported by 17% and 8% of patients in the pla-
cebo/14-mg and placebo/7-mg groups, respectively,
and by #5% of patients in the other treatment
groups (table e-3C). One case of hair thinning was
considered serious by the treating physician (14-mg/
14-mg group). No cases led to treatment discontinu-
ation. The majority of patients recovered without
requiring corrective treatment. In extension year 1,
there was a higher incidence of first AE of hair thin-
ning in patients switching from placebo to terifluno-
mide (placebo/14 mg, 15.1%; placebo/7 mg, 6.9%)
than in patients continuing with teriflunomide
(14 mg/14 mg, 1.2%; 7 mg/7 mg, 2.0%). In subse-
quent years, no such pattern was evident.
Hypertension.Hypertension was reported in 10.8%,
6.6%, 6.3%, and 6.9% of patients in the 14-mg/
14-mg, placebo/14-mg, 7-mg/7-mg, and placebo/
7-mg groups, respectively (table e-3C). These events
occurred in similar proportions of patients with
(7.7%) and without (8.0%) a history of hypertension
or antihypertensive treatment. In extension year 1, a
first AE of hypertension was more common in pa-
tients switching from placebo (placebo/14 mg,
5.7%; placebo/7 mg, 5.4%) compared with those
continuing on active treatment (14 mg/14 mg,
4.4%; 7 mg/7 mg, 3.9%). No events were considered
serious, and there were no discontinuations owing to
hypertension.
Pregnancies.Despite the requirement for use of reli-
able contraception, a total of 14 pregnancies occurred
during the extension study. Seven occurred in female
patients (6 discontinued treatment, table e-3B), re-
sulting in 4 live births, 1 induced abortion, and 2
spontaneous abortions; 7 occurred in partners of male
patients, resulting in 5 live births, 1 induced abortion,
and 1 spontaneous abortion. There were no signs of
structural or functional deficits in the newborns.
Deaths. Three deaths were reported, but none was
considered by investigators to be related to study
treatment. These occurred as follows: death in sleep
from cause unknown (no autopsy performed) of a
44-year-old man who had received 3.8 years of treat-
ment with teriflunomide 7 mg; death from unknown
cause but with brain pathology consistent with an
acute attack of MS in a 42-year-old woman with
advanced MS who had received teriflunomide 7 mg
for 3 years; and death from acute heart failure in
the context of chronic coronary artery disease in a
37-year-old man who had received teriflunomide
14 mg for 3.5 years.
Efficacy outcomes. Clinical outcomes.There was a notice-
able drop in ARR for the group of patients who
received placebo in the core study as they switched
to teriflunomide in the extension (figure 2A). ARRs
declined over the extension and were numerically
lower at the cutoff date than at the end of the core
study in all treatment groups. The ARR for the com-
bined core plus extension study periods was lower in
patients who received teriflunomide throughout com-
pared with those who began teriflunomide 7 mg after
108 weeks of placebo treatment (14-mg/14-mg
group, p 5 0.003; 7-mg/7-mg group, p 5 0.022).
There was a similar (albeit nonsignificant) effect for
patients who received teriflunomide throughout com-
pared with the placebo/14-mg group. Regardless of
their dose allocation,$55% of patients did not expe-
rience a relapse in the extension (table 3).
Overall, patients exhibited minimal disability pro-
gression: mean EDSS scores remained stable over
time in the extension (figure 2B) with mean increases
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Figure 2 Efficacy outcomes in the core Teriflunomide Multiple Sclerosis Oral (TEMSO) and extension studies (modified intent-to-treat
population)
(A) Annualized relapse rate. (B) Mean EDSS score. (C) Number of Gd-enhancing T1 lesions. a Patients receiving placebo in the core study are shown as one
group for this analysis. Week refers to time since start of core study. Week 108 is end of core study/start of extension study. Total number of Gd-enhancing
T1 lesions defined as all lesions enhanced on T1 scan. *p,0.005 compared with pooled placebo group; **p,0.05 compared with placebo/7-mg group. CI5
confidence interval; EDSS 5 Expanded Disability Status Scale; Gd 5 gadolinium.
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Table 3 Clinical and MRI outcomes in the core Teriflunomide Multiple Sclerosis Oral (TEMSO) and extension studies (modified intent-to-treat
population)
Teriflunomide
14 mg/14 mg
Placebo/
teriflunomide
14 mg
Teriflunomide
7 mg/7 mg
Placebo/
teriflunomide
7 mg Placeboa
Clinical outcomes
Relapse
No. 251 108 252 129 237
Adjusted annualized
relapse rate
Core 0.291* 0.301* 0.440
Extension 0.171 0.177 0.198 0.225
Core 1 extensionb 0.215† 0.260 0.240† 0.324
Patients with ‡1 relapse,
n (%)
96 (38.2) 101 (40.1)
Core 107 (42.6) — 105 (41.7) — 117 (49.4)
Extension 141 (56.2) 45 (41.7) 148 (58.7) 54 (41.9) —
Core 1 extensionb 68 (63.0) 81 (62.8) —
12-Week disability
progressionc
No. 251 108 252 129 237
Patients with progression,
n (%)
Core 48 (19.1) — 52 (20.6) — 63 (26.6)
Core 1 extensionb 98 (39.0) 44 (40.7) 97 (38.5) 59 (45.7) —
Probability of disability
progression (95% CI)
Core 0.191‡ (0.143, 0.240) — 0.206 (0.156, 0.256) — 0.266 (0.210, 0.322)
Core 1 extensionb 0.420 (0.354, 0.485) 0.420 (0.323, 0.517) 0.433 (0.363, 0.504) 0.480 (0.387, 0.572) —
24-Week disability
progressionc
No. 251 108 252 129 237
Patients with progression,
n (%)
Core 36 (14.3) — 36 (14.3) — 42 (17.7)
Core 1 extensionb 88 (35.1) 42 (38.9) 83 (32.9) 45 (34.9) —
Probability of disability
progression (95% CI)
Core 0.143 (0.100, 0.187) — 0.143 (0.100, 0.186) — 0.177 (0.129, 0.226)
Core 1 extensionb 0.382 (0.317, 0.446) 0.403 (0.306, 0.500) 0.377 (0.308, 0.446) 0.367 (0.279, 0.455) —
MRI outcomes (week 252)
No. of Gd-enhancing T1
lesions
No. 157 68 149 74 —
Mean (SD) 0.210 (0.621) 0.176 (0.545) 0.564 (1.578) 0.595 (2.323) —
No. 156 66 147 74 —
Mean (SD) change from BLd 20.885 (2.522) 21.152 (2.543) 20.769 (3.871) 20.743 (3.101) —
Active scans
No. 157 68 149 74 —
Patients (% of patients)
with ‡1
Gd-enhancing T1 lesion
20 (12.7) 8 (11.8) 29 (19.5) 11 (14.9) —
Continued
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from core study baseline to week 348 of 0.46, 0.45,
0.22, and 0.24 points in the 14-mg/14-mg, placebo/
14-mg, 7-mg/7-mg, and placebo/7-mg groups, respec-
tively. It is worth noting that teriflunomide 14 mg
reduced the risk of disability progression in the core
study (p 5 0.03 vs placebo), and after a sustained
period with all patients receiving active treatment,
there was a low rate of progression in all groups. Over
the combined core and extension periods, the proba-
bility of disability progression sustained for either 12 or
24 weeks was ,0.5 in all groups, and over half of
patients did not experience any progression (table 3).
MRI outcomes. We observed a decrease in the mean
number of Gd-enhancing T1 lesions for the group of
patients who received placebo in the core study as
they switched to teriflunomide in the extension;
mean Gd-enhancing T1 lesion count remained low
thereafter (figure 2C). Most patients ($80%) did
not have Gd-enhancing T1 lesions during the study
(table 3). Total lesion volume, and its component
measures T1 and T2 lesion volume, remained rela-
tively constant to week 252 (table 3).
DISCUSSION This long-term extension of the
pivotal phase 3 TEMSO trial indicated that both
doses of teriflunomide were well-tolerated and had a
consistent safety profile with up to 9 years of
teriflunomide exposure. The nature and pattern of
AEs reported with longer term exposure were
consistent with those observed in the core phase of
the TEMSO study3 and were in line with safety
observations reported in other teriflunomide clinical
trials.2,4,5,11 No new or unexpected AEs were reported
with longer term exposure. Some of the AEs most
commonly reported with teriflunomide, such as
transient ALT elevations and hair thinning,
appeared early in treatment; first incidence of these
events then declined with continuing exposure.
The TEMSO extension study is markedly larger
than the phase 2 extension, including approximately
Table 3 Continued
Teriflunomide
14 mg/14 mg
Placebo/
teriflunomide
14 mg
Teriflunomide
7 mg/7 mg
Placebo/
teriflunomide
7 mg Placeboa
Total lesion volume, mLe
No. 158 68 149 75 —
Mean (SD) 18.195 (15.190) 21.533 (22.045) 22.083 (23.750) 19.741 (17.835) —
No. 158 66 147 75 —
Mean (SD) change from BLd 2.699 (7.197) 2.989 (6.446) 3.707 (9.739) 4.880 (8.712) —
Mean (SD) % change
from BLd
35.653 (74.178) 32.846 (70.239) 35.921 (81.985) 56.166 (118.768) —
T1 lesion volume, mL
No. 158 68 149 75 —
Mean (SD) 3.524 (3.196) 4.174 (4.492) 4.384 (5.097) 3.647 (3.796) —
No. 158 66 147 75 —
Mean (SD) change from BLd 0.899 (1.268) 1.237 (1.670) 1.260 (2.149) 1.028 (1.642) —
T2 lesion volume, mL
No. 158 68 149 75 —
Mean (SD) 14.671 (12.550) 17.359 (17.851) 17.699 (19.352) 16.094 (14.735) —
No. 158 66 147 75 —
Mean (SD) change from BLd 1.800 (6.524) 1.752 (5.536) 2.447 (8.320) 3.852 (7.752) —
Abbreviations: BL 5 baseline (core study week 0); CI 5 confidence interval; Gd 5 gadolinium.
Disability progression: disability progression sustained for 12 weeks. Total lesion volume defined as total volumes of T2-hyperintense and T1-hypointense
lesions, without double counting, as measured by MRI. Total number of Gd-enhancing T1 lesions defined as all lesions enhanced on current T1 scan. Count
for lesions and active scans is at week 252.
a Patients who received placebo in the core study and went on to enter the extension.
b Including data from up to 7 years, since the start of the core TEMSO study.
c Kaplan-Meier estimate.
dCore study baseline.
eGd-enhancing lesions plus unenhanced new and substantially enlarged T2-hyperintense lesions.
*p , 0.005 vs placebo (core study).
†p , 0.05 vs placebo/7 mg (core plus extension), based on x2 test from the estimated rate ratios from the Poisson model.
‡p , 0.05 vs placebo (core study), derived from a log-rank test with treatment group as test variable, and region and baseline Expanded Disability Status
Scale score as stratification factors.
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5 times more patients. The safety observations from
this study are consistent with those from the phase
2 extension, during which the nature and frequency
of AEs did not change with up to 8.5 years of contin-
ued exposure.6 Malignancies were infrequent and
there was no specific pattern of tumor types; no
hematologic cancers were recorded. Combined with
the low frequencies of serious infections, neutropenia,
and leukopenia, this suggests that teriflunomide does
not adversely affect immune function.
Similar to observations in the phase 2 extension,6
disability progression, ARR, and MRI activity re-
mained low throughout the TEMSO extension, indi-
cating that teriflunomide efficacy is maintained with
long-term treatment. We observed marginally greater
mean increases in EDSS in the 14-mg groups com-
pared with the 7-mg groups; in contrast, in the phase
2 extension study, EDSS increases were smaller in the
14-mg group.6 As patients who received placebo in
the core study switched to receive teriflunomide,
there was a noticeable reduction in ARR and in the
number of Gd-enhancing T1 lesions, which was sus-
tained with continued treatment. A decline in Gd-
enhancing T1 lesion numbers as placebo group
patients entered the extension and low lesion num-
bers in patients continuing on active treatment were
also observed in the phase 2 extension study.6
Although this study was not designed to compare
immediate vs delayed treatment, post hoc analyses
of ARR for the whole treatment period suggest that
teriflunomide treatment should begin as early as pos-
sible to maximize benefits for the patient.
There are limitations associated with all long-term
extensions that should be highlighted.12 First, there is
no placebo control group during the extension, which
limits interpretation. Second, long-term extensions
may preferentially retain patients responding well to
therapy (informative censoring), thus biasing the out-
comes observed.12 However, although a number of
patients did drop out over the course of the TEMSO
extension, 63% of patients who entered the study re-
mained in the extension at the interim analysis cutoff,
and only 43 patients (6%) discontinued treatment for
perceived lack of efficacy. This high retention rate
could suggest high patient satisfaction with terifluno-
mide, an observation also made in other studies.5
Overall, the results of this study provide further evi-
dence that the effects of teriflunomide are maintained
with longer term treatment and also support previous
observations that teriflunomide has a well-characterized
and manageable long-term safety profile.
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